Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Milei Threatens Falkland Oil Firms With Sanctions 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Xiaomi Shares Jump on Europe EV Expansion Plan 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Add as a preferred source on Google
SAN DIEGO, March 06, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 30th Annual ROTH Conference at 1:00 pm PT (4:00 pm ET) on Tuesday, March 13, 2018, at the Ritz Carlton in Dana Point, CA.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact:
Patricia Bitar
Chief Financial Officer
(858) 550‐0780 ext. 223
[email protected]
Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
[email protected]
